RXRX - Recursion Pharmaceuticals GAAP EPS of -$0.39 beats by $0.03 revenue of $13.79M beats by $0.72M
2024-05-09 17:05:02 ET
More on Recursion Pharmaceuticals
- Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate
- Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)
- Recursion Pharmaceuticals, Inc. (RXRX) Q4 2023 Earnings Call Transcript
- Recursion Pharmaceuticals Q1 2024 Earnings Preview
- Crispr, Intellia, and Recursion gain as Ark ETFs boost stakes